Copper (64Cu) Oxodotreotide

Copper (64Cu) oxodotreotide
INN: Copper (⁶⁴Cu) oxodotreotide
Names
Trade names	Detectnet
Other names	Copper Cu 64 dotatate
	IUPAC name 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+);
Clinical data
Drug class	Radioactive diagnostic agent
Main uses	Positron emission tomography (PET) of neuroendocrine tumors (NETs)
Side effects	Nausea, vomiting, flushing
Pregnancy; category	US: N (Not classified yet); ;
Routes of; use	Intravenous
Legal
License data	US DailyMed: Detectnet;
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C65H88CuN14O19S2
Molar mass	1497.16 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O.[Cu+2];
	InChI InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0; Key:IJRLLVFQGCCPPI-NVGRTJHCSA-L;

Copper (⁶⁴Cu) oxodotreotide, sold under the brand name Detectnet, is a radioactive diagnostic agent used in positron emission tomography (PET) of neuroendocrine tumors (NETs).^[1] Specifically it is used in adults with somatostatin receptor positive disease.^[1] It is given by injection into a vein.^[1]

Common side effects include nausea, vomiting, and flushing.^[1] Other side effects include radiation exposure and allergic reactions.^[1] It interacts with somatostatin analogs.^[1] Use during pregnancy may harm the baby.^[1] It works by binding to somatostatin receptor, particularly subtype 2 receptors.^[1]

Copper (⁶⁴Cu) oxodotreotide was approved for medical use in the United States in 2020.^[1] In the United States it costs about 3,900 USD for a vial as of 2022.^[2]

Medical uses[edit | edit source]

Dosage[edit | edit source]

It is typically used at a dose of 148 MBq (4 mCi).^[1]

History[edit | edit source]

The U.S. Food and Drug Administration (FDA) approved copper ⁶⁴Cu dotatate based on data from two trials that evaluated 175 adults.^[3]

Trial 1 evaluated adults, some of whom had known or suspected NETs and some of whom were healthy volunteers.^[3] The trial was conducted at one site in the United States (Houston, TX).^[3] Both groups received copper ⁶⁴Cu dotatate and underwent PET scan imaging.^[3]

Trial 2 data came from the literature-reported trial of 112 adults, all of whom had history of NETs and underwent PET scan imaging with copper ⁶⁴Cu dotatate.^[3] The trial was conducted at one site in Denmark.^[3] In both trials, copper ⁶⁴Cu dotatate images were compared to either biopsy results or other images taken by different techniques to detect the sites of a tumor.^[3] The images were read as either positive or negative for presence of NETs by three independent image readers who did not know participant clinical information.^[3]

References[edit | edit source]

↑ ^1.00 ^1.01 ^1.02 ^1.03 ^1.04 ^1.05 ^1.06 ^1.07 ^1.08 ^1.09 ^1.10 ^1.11 ^1.12 ^1.13 "Detectnet- copper cu 64 dotatate injection, solution". DailyMed. 14 September 2020. Archived from the original on 1 November 2022. Retrieved 24 September 2020.
↑ "Detectnet Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2022. Retrieved 3 November 2022.
↑ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 ^3.6 ^3.7 "Drug Trials Snapshots: Detectnet". U.S. Food and Drug Administration (FDA). 3 September 2020. Archived from the original on 21 September 2020. Retrieved 10 September 2020. This article incorporates text from this source, which is in the public domain.

External links[edit | edit source]

"Copper dotatate Cu-64". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-05-21. Retrieved 2022-10-20.
"copper Cu 64 dotatate injection safety data sheet" (PDF). Curium US LLC. 15 March 2020. Archived (PDF) from the original on 27 October 2020. Retrieved 20 October 2022.

This pharmacology-related article is a stub. You can help MDWiki by expanding it.

[PI2022-1] 1.00 ^1.01 ^1.02 ^1.03 ^1.04 ^1.05 ^1.06 ^1.07 ^1.08 ^1.09 ^1.10 ^1.11 ^1.12 ^1.13 "Detectnet- copper cu 64 dotatate injection, solution". DailyMed. 14 September 2020. Archived from the original on 1 November 2022. Retrieved 24 September 2020.

[2] "Detectnet Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2022. Retrieved 3 November 2022.

[FDA_snapshot-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 ^3.6 ^3.7 "Drug Trials Snapshots: Detectnet". U.S. Food and Drug Administration (FDA). 3 September 2020. Archived from the original on 21 September 2020. Retrieved 10 September 2020. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]